Member support:
1300 854 838
Report Incident
Login
Join PDL

2024-2025 most reported medicines

  • Written by: Amy Minion and Gary West
National
Each year, PDL reviews data reported by members, and reflects on the challenges pharmacists have faced, while extracting insights from the patterns/trends that emerged. Below are the top 10 most reported medicines in the 2024-2025 financial year: Oxycodone (immediate and slow release, individually and in combination) Semaglutide Tapentadol Methylphenidate Prednisone/olone Tirzepatide Oestrogen (oral and patches, individually and in combination but excludes oral contraceptives) Lisdexamfetamine Paracetamol and codeine combinations Levothyroxine The PDL Prof…

Member only access

This content is available to PDL members only.
To continue reading please log in to the member portal or join PDL today.

Login
Join PDL
Share this article

Related Practice Alerts

New NSW medicines and poisons legislation now in effect
10 November 2026
NSWProfessional activitiesRegulatory and compliancePractice support, tips and tools
Learn more
The myth of the owing prescription
15 October 2026
NationalDispensingRegulatory and compliancePractice support, tips and tools
Learn more
Is this the right jab? RSV vaccine selection reminder
25 August 2026
NationalDispensingProfessional activitiesVaccinationRegulatory and compliancePractice support, tips and tools
Learn more
Join PDL
Log in

PDL Update

The global Microsoft issues have caused
significant delays in communication.

If your matter is urgent and you need to speak to PDL,
don’t hesitate to get in touch with us on 1300 854 838.